Lucanthone and its derivative hycanthone inhibit apurinic endonuclease-1 (APE1) by direct protein binding.
Lucanthone and hycanthone are thioxanthenone DNA intercalators used in the 1980s as antitumor agents. Lucanthone is in Phase I clinical trial, whereas hycanthone was pulled out of Phase II trials. Their potential mechanism of action includes DNA intercalation, inhibition of nucleic acid biosyntheses...
Saved in:
Main Authors: | Mamta D Naidu, Rakhi Agarwal, Louis A Pena, Luis Cunha, Mihaly Mezei, Min Shen, David M Wilson, Yuan Liu, Zina Sanchez, Pankaj Chaudhary, Samuel H Wilson, Michael J Waring |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2011
|
Subjects: | |
Online Access: | https://doaj.org/article/8d44bed6eda94a51a3989f04a3a89c3e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Changes in the Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1(APE1/Ref-1) Level during Cancer Surgery: An Observational Study
by: Yumin Jo, et al.
Published: (2021) -
Mild phenotype of knockouts of the major apurinic/apyrimidinic endonuclease APEX1 in a non-cancer human cell line.
by: Daria V Kim, et al.
Published: (2021) -
The antioxidant and DNA-repair enzyme apurinic/apyrimidinic endonuclease 1 limits the development of tubulointerstitial fibrosis partly by modulating the immune system
by: Keisuke Maruyama, et al.
Published: (2019) -
New Horizons for the Roles and Association of APE1/Ref-1 and ABCA1 in Atherosclerosis
by: Chen W, et al.
Published: (2021) -
Molecular snapshots of APE1 proofreading mismatches and removing DNA damage
by: Amy M. Whitaker, et al.
Published: (2018)